{"id":47282,"date":"2022-08-15T15:01:44","date_gmt":"2022-08-15T13:01:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/"},"modified":"2022-08-15T15:01:44","modified_gmt":"2022-08-15T13:01:44","slug":"immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/","title":{"rendered":"ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology"},"content":{"rendered":"<div>\n<p>\n<b>Convincing evidence of efficacy and protection demonstrated again<\/b>\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220815005130\/en\/1543505\/5\/Immunogenx-logo2016%28trans%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220815005130\/en\/1543505\/21\/Immunogenx-logo2016%28trans%29.jpg\"><\/a><\/p>\n<p class=\"bwalignl\">NEWPORT BEACH, Calif.&#8211;(BUSINESS WIRE)&#8211;ImmunogenX is pleased to report the successful completion of the CeliacShield\u2122 trial (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03585478&amp;esheet=52812815&amp;newsitemid=20220815005130&amp;lan=en-US&amp;anchor=NCT03585478&amp;index=1&amp;md5=2e807891b7ac226d94488e96063f3ba7\" rel=\"nofollow noopener\" shape=\"rect\">NCT03585478<\/a>), focused on treating celiac disease (CeD) patients, will be published in the premier journal <i>Gastroenterology<\/i> and is entitled:\n<\/p>\n<p class=\"bwalignc\">\nLatiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients with Celiac Disease Exposed to a Gluten Challenge<br \/>\n<br \/><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gastrojournal.org%2Farticle%2FS0016-5085%252822%252900901-5%2Ffulltext&amp;esheet=52812815&amp;newsitemid=20220815005130&amp;lan=en-US&amp;anchor=doi.org%2F10.1053%2Fj.gastro.2022.07.071&amp;index=2&amp;md5=1632eca1823f6607f349a59a5a8446be\" rel=\"nofollow noopener\" shape=\"rect\">doi.org\/10.1053\/j.gastro.2022.07.071<\/a>\n<\/p>\n<p>\nThis work was performed at Mayo Clinic under Principal Investigator Joseph Murray, MD and resulted in:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nConfirmed findings of a prior European study (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01255696&amp;esheet=52812815&amp;newsitemid=20220815005130&amp;lan=en-US&amp;anchor=NCT01255696&amp;index=3&amp;md5=32658e6bb61f6f797827a1d8a87c8f45\" rel=\"nofollow noopener\" shape=\"rect\">NCT01255696<\/a>) demonstrating that latiglutenase protects patients from mucosal damage induced by dietary gluten.\n<\/li>\n<li>\nUsed a celiac disease specific patient reported outcomes (PRO) instrument to demonstrate that latiglutenase also protects against adverse clinical effects of gluten consumption.\n<\/li>\n<li>\nFirst-time clinical-trial use of a gluten-immunogenic peptide (GIP) in urine assay to demonstrate ~95% elimination of gluten in the stomach (p &lt; 0.0001) by latiglutenase.\n<\/li>\n<\/ul>\n<p>\nPeter HR Green, MD of Columbia University remarks, \u201cAs an independent observer for this trial and a site Principal Investigator for another latiglutenase trial, I am happy to state that latiglutenase offers the potential for significant improvement in the pain and suffering and quality of life of celiac disease patients. These patients, despite strict adherence to a gluten-free diet, remain exposed to gluten in everyday life and suffer the consequences despite their best dietary efforts.\u201d\n<\/p>\n<p>\nJack Syage, PhD and CEO of ImmunogenX, states, \u201cWe are excited by the continued success of latiglutenase as a leading therapeutic candidate for celiac disease patients as an adjunct to a gluten-free diet. Our mission to improve the lives of celiac disease patients is inspired by members of our team who are afflicted with this disease and are the driving force to achieving success to benefit all others.\u201c\n<\/p>\n<p>\nThis clinical trial was sponsored by the National Institutes of Health\u2019s (NIH) National Center for Complementary and Integrative Health (NCCIH).* Further information can be found at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Celiacshield.com&amp;esheet=52812815&amp;newsitemid=20220815005130&amp;lan=en-US&amp;anchor=Celiacshield.com&amp;index=4&amp;md5=947584e050cd659c13fe53c63b996c31\" rel=\"nofollow noopener\" shape=\"rect\">Celiacshield.com<\/a>.\n<\/p>\n<p class=\"bwmarginl1\">\n* The content of this news release is solely the responsibility of ImmunogenX and does not necessarily represent the official views of the National Institutes of Health.\n<\/p>\n<p>\n<b>About ImmunogenX<\/b>\n<\/p>\n<p>\nImmunogenX, Inc. is a clinical-stage biopharmaceutical company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a diagnostic tool for celiac disease management (CypCel\u2122) as a minimally-invasive monitor of villus health to follow the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Immunogenx.com&amp;esheet=52812815&amp;newsitemid=20220815005130&amp;lan=en-US&amp;anchor=www.immunogenx.com&amp;index=5&amp;md5=54f7bac1736b1fed8313048c0b45ab6c\" rel=\"nofollow noopener\" shape=\"rect\">www.immunogenx.com<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nMatthew Dickason, MBA<br \/>\n<br \/>Chief Operating Officer<br \/>\n<br \/>(949) 679-0900<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#x6f;:&#x6d;&#100;&#x69;&#x63;k&#x61;&#115;&#x6f;&#x6e;&#64;&#x69;&#109;&#x6d;&#x75;n&#x6f;&#103;&#x65;&#x6e;x&#x2e;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">mdic&#107;&#97;&#115;&#111;&#110;&#x40;&#x69;&#x6d;&#x6d;&#x75;&#x6e;&#x6f;genx&#46;&#99;&#111;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Convincing evidence of efficacy and protection demonstrated again NEWPORT BEACH, Calif.&#8211;(BUSINESS WIRE)&#8211;ImmunogenX is pleased to report the successful completion of the CeliacShield\u2122 trial (NCT03585478), focused on treating celiac disease (CeD) patients, will be published in the premier journal Gastroenterology and is entitled: Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients with Celiac Disease &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47282","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Convincing evidence of efficacy and protection demonstrated again NEWPORT BEACH, Calif.&#8211;(BUSINESS WIRE)&#8211;ImmunogenX is pleased to report the successful completion of the CeliacShield\u2122 trial (NCT03585478), focused on treating celiac disease (CeD) patients, will be published in the premier journal Gastroenterology and is entitled: Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients with Celiac Disease ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-15T13:01:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220815005130\/en\/1543505\/21\/Immunogenx-logo2016%28trans%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology\",\"datePublished\":\"2022-08-15T13:01:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\\\/\"},\"wordCount\":445,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220815005130\\\/en\\\/1543505\\\/21\\\/Immunogenx-logo2016%28trans%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\\\/\",\"name\":\"ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220815005130\\\/en\\\/1543505\\\/21\\\/Immunogenx-logo2016%28trans%29.jpg\",\"datePublished\":\"2022-08-15T13:01:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220815005130\\\/en\\\/1543505\\\/21\\\/Immunogenx-logo2016%28trans%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220815005130\\\/en\\\/1543505\\\/21\\\/Immunogenx-logo2016%28trans%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/","og_locale":"en_US","og_type":"article","og_title":"ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology - Pharma Trend","og_description":"Convincing evidence of efficacy and protection demonstrated again NEWPORT BEACH, Calif.&#8211;(BUSINESS WIRE)&#8211;ImmunogenX is pleased to report the successful completion of the CeliacShield\u2122 trial (NCT03585478), focused on treating celiac disease (CeD) patients, will be published in the premier journal Gastroenterology and is entitled: Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients with Celiac Disease ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-15T13:01:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220815005130\/en\/1543505\/21\/Immunogenx-logo2016%28trans%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology","datePublished":"2022-08-15T13:01:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/"},"wordCount":445,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220815005130\/en\/1543505\/21\/Immunogenx-logo2016%28trans%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/","url":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/","name":"ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220815005130\/en\/1543505\/21\/Immunogenx-logo2016%28trans%29.jpg","datePublished":"2022-08-15T13:01:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220815005130\/en\/1543505\/21\/Immunogenx-logo2016%28trans%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220815005130\/en\/1543505\/21\/Immunogenx-logo2016%28trans%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/immunogenx-and-mayo-clinic-celiac-disease-study-published-in-gastroenterology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47282"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47282\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}